Glycosylation of proteins and microangiopathy.
Diabetic complications may result from chronic glycosylation of protein within cells and in the extracellular matrix. Prevention of glycosylation with aminoguanidine has forestalled complications in experimental diabetes.
Brownlee
M
M
Albert Einstein College of Medicine, Bronx, New York.
D000419:Albuminuria / Q000453:epidemiology / Q000209:etiology / Q000652:urine; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D004075:Diglycerides / Q000378:metabolism; D004285:Dogs; D005920:Glomerular Mesangium / Q000187:drug effects / Q000473:pathology; D006019:Glycolysis / Q000502:physiology; D006031:Glycosylation; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007294:Inositol / Q000378:metabolism; D051381:Rats; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D013012:Sorbitol / Q000378:metabolism
D004075:Diglycerides; D006146:Guanidines; D007294:Inositol; D013012:Sorbitol; D000254:Sodium-Potassium-Exchanging ATPase; C004479:pimagedine